LEO Pharma to present new data in moderate-to-severe atopic dermatitis and chronic hand eczema at the 31st EADV Congress
Retrieved on:
Thursday, August 25, 2022
Health, Pharmaceutical, Janus, Tralokinumab, Jake Virtanen, Systematic review, JT, Safety, Pain, Research, Atopic dermatitis, Ageing, Swelling, United Arab Emirates, BioDrugs, Disease, Itch, Autoimmune disease, JAAD, Diagnosis, Science, Poster, HE, Blister, DKK, Annual general meeting, European Academy of Allergy and Clinical Immunology, Immune system, Prevalence, CHE, Thyssen, Adult, AD, Epidemiology, Congress, JAK, Leo Pharma, Journal of the European Academy of Dermatology and Venereology, Patient, Vaccine, Pharmaceutical industry, Medical device, Hospital, Venereology, EU, Veni, vidi, vici, Dermatology
LEO Pharma is headquartered in Denmark with a global team of 5,800 people, serving millions of patients across the world.
Key Points:
- LEO Pharma is headquartered in Denmark with a global team of 5,800 people, serving millions of patients across the world.
- 3 years of tralokinumab treatment provides long-term disease control as demonstrated by clinically meaningful outcomes in moderate-to-severe atopic dermatitis.
- Tralokinumab demonstrated a consistent safety profile with up to 42 months of treatment in moderate-to-severe atopic dermatitis: including adverse events of special interest.
- Safety of tralokinumab in paediatric patients aged 12-17 with moderate-to-severe atopic dermatitis: results from the phase 3 ECZTRA 6 trial.